Welcome to our dedicated page for Ikena Oncology news (Ticker: IKNA), a resource for investors and traders seeking the latest updates and insights on Ikena Oncology stock.
This page provides a historical news archive for Ikena Oncology, Inc., which traded on Nasdaq under the symbol IKNA before its merger with Inmagene Biopharmaceuticals and subsequent name change to neBio, Inc. The articles collected here trace how Ikena evolved from a targeted oncology company into part of a broader clinical-stage biotechnology organization whose stock now trades under the ticker IMA.
Earlier news under IKNA focuses on Ikena’s targeted oncology programs, including IK-930, a TEAD1-selective Hippo pathway inhibitor, and IK-595, a MEK-RAF molecular glue studied in patients with RAS and RAF mutant cancers. Releases detail clinical progress such as Phase 1 dose escalation, pharmacokinetics and pharmacodynamics observations, and strategic decisions like the discontinuation of IK-930 and workforce restructuring. Financial updates outline Ikena’s cash position, research and development spending, and its evaluation of strategic options for the company and its pipeline.
Subsequent news documents the agreement and completion of a merger with Inmagene Biopharmaceuticals, the approval of the transaction by Ikena stockholders, and the implementation of a 1-for-12 reverse stock split. Coverage explains that the combined company would operate as neBio, Inc., focus on developing -007, a non-depleting anti-OX40 monoclonal antibody for immunological and inflammatory diseases, and trade on Nasdaq under the symbol IMA. Additional items describe the establishment of contingent value rights for Ikena’s legacy assets and governance and compensation plans for the combined company.
Investors and researchers can use this IKNA news archive to follow the sequence of clinical, financial, and corporate events that led from Ikena’s oncology-focused operations to its transformation into neBio, Inc. and the shift in emphasis toward immunological and inflammatory disease programs centered on -007.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.